GFH009 plus zanubrutinib for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of large B-cell lymphoma that came back or didn't respond to at least 2 treatments, one of which included a chemo drug called an anthracycline and the drug rituximab.
- You are not able or suitable to have a stem cell transplant.
- You have at least one lymphoma tumor that can be measured on a scan.
- Your lymphoma has not spread to your brain or spinal cord.
- You have not had chemotherapy or other cancer drugs in the last month, or CAR-T therapy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a combination of targeted therapy (zanubrutinib) with standard chemotherapy (G-CHOP) for people with untreated follicular lymphoma that is intermediate or high risk. The goal is to see if this combination can improve outcomes compared to standard care.
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.